Study of Glecaprevir/Pibrentasvir to Assess Safety Through Real-World Data
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- AbbVie
- Trial code
- NCT07419347
- Record updated
- 16 April 2026
- Original description
The objective of this study is to assess the safety, tolerability and effectiveness of 8-week Glecaprevir/Pibrentasvir (G/P) in participants taking either prescribed or illicit drugs.Read full original descriptionShow less
Retrospective Analysis of Glecaprevir/Pibrentasvir Safety and Concomitant Medications Through Integrated Real-World Data
The objective of this study is to assess the safety, tolerability and effectiveness of 8-week Glecaprevir/Pibrentasvir (G/P) in participants taking either prescribed or illicit drugs.
Inclusion: Prescribed 8 weeks of Glecaprevir/Pibrentasvir (G/P); Treatment-naïve (for the current infection, participants that may have had prior infections which were resolved with treatment are considered naive for current infection as long as they have not received any treatment for the current infection.); Is concomitantly on one or more prescription medications or illicit drugs.
Exclusion: Treated with DAAs other than G/P; History of decompensated cirrhosis; Had Hepatitis-B virus (HBV) infection; Had hepatocellular carcinoma (HCC).